Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Pulsed Field Ablation Outcomes in Atrial Fibrillation: Randomized Comparison to Traditional Ablation

Official title: Pulsed Field Ablation for Atrial Fibrillation Including Posterior Wall and Linear Ablation: A Randomized Controlled Trial of Safety and Efficacy (POWER-AF)

Run by China National Center for Cardiovascular Diseases · NCT07601763 · Data updated 2026-11-12

This study tests pulsed field ablation versus conventional radiofrequency ablation in adults with atrial fibrillation to see which method better preserves heart rhythm.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment1574 (estimated)
SponsorChina National Center for Cardiovascular Diseases
Government
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedApril 16, 2025
Main results expectedNovember 30, 2027
Study endsNovember 30, 2028
Registry record updatedMay 28, 2026
Trial IDNCT07601763 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with atrial fibrillation who are suitable for catheter ablation and can provide informed consent.

Probably not a fit

Patients with contraindications to ablation or previous ablation, recent cardiac events, or other exclusion criteria may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares pulsed field ablation (PFA) with radiofrequency ablation (RFA) for treating atrial fibrillation in adults. Participants undergo either PFA or RFA to determine safety and effectiveness in maintaining sinus rhythm. The study utilizes predefined criteria to enroll eligible patients and excludes those with recent cardiac events or contraindications to ablation. Outcomes will inform whether the novel PFA approach offers advantages over traditional energy delivery. The trial is conducted under the banner of the China National Center for Cardiovascular Diseases at Fuwai Hospital.

Why it matters

Potential benefit: If successful, patients may experience better rhythm control and fewer procedure-related complications with pulsed field ablation.

How similar studies have gone: Previous studies have demonstrated the effectiveness of catheter ablation for AF, but the relative advantages of pulsed field ablation require further confirmation.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Atrial fibrillation patients who will accept catheter ablation.
2. Age ≥ 18.
3. Be capable of understanding and signing the informed consent form.

Exclusion Criteria:

1. Have contraindications for catheter ablation (such as atrial thrombosis, decompensated heart failure, etc.)
2. Have accepted catheter ablation before.
3. Myocardial infarction, or any cardiac interventional/surgery has been performed within 3 months.
4. Had a stroke or transient ischemic attack within 6 months.
5. Allergy to iodine contrast agents.
6. Participate in clinical trials related to other drugs or devices.
7. Pregnant women, lactating women, or women with plans to become pregnant shortly.
8. Active stage of infection.
9. Secondary atrial fibrillation, such as combined with rheumatic heart disease, hypertrophic cardiomyopathy, etc.
10. Patients who do not agree to be enrolled or are unable to cooperate to complete the study

Where it's running

  • National Cardiovascular Diseases Center, Fuwai Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.